Broad, comprehensive immune profiling by RNA-seq that includes PD-L1 in addition to expression for many other immune genes can be run in parallel with comprehensive genomic profiling to measure the growing spectrum of biomarkers needed for treatment selection in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.